Fernanda S. Tonin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9222408/publications.pdf

Version: 2024-02-01

279487 276539 2,051 86 23 41 citations h-index g-index papers 86 86 86 3587 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Oral antifungal therapies for toenail onychomycosis: a systematic review with network meta-analysis toenail mycosis: network meta-analysis. Journal of Dermatological Treatment, 2022, 33, 121-130.	1.1	8
2	Influence of foods and nutrients on COVID-19 recovery: A multivariate analysis of data from 170 countries using a generalized linear model. Clinical Nutrition, 2022, 41, 3077-3084.	2.3	27
3	Methodological standards for conducting and reporting meta-analyses: Ensuring the replicability of meta-analyses of pharmacist-led medication review. Research in Social and Administrative Pharmacy, 2022, 18, 2259-2268.	1.5	9
4	Solid Oral Dosage Forms Use in Adults with Neurological Disorders and Swallowing Difficulties: A Scoping Review. Dysphagia, 2022, 37, 909-922.	1.0	2
5	Methodological quality and risk of bias of meta-analyses of pharmacy services: A systematic review. Research in Social and Administrative Pharmacy, 2022, 18, 2403-2409.	1.5	3
6	Confusing terminology used in the abbreviation of pharmacy journal names. Research in Social and Administrative Pharmacy, 2022, 18, 3463-3465.	1.5	7
7	Efficacy and safety of daily treatments for drug-susceptible pulmonary tuberculosis: a systematic review and network meta-analysis. Journal of Pharmacy and Pharmacology, 2022, 74, 905-917.	1.2	4
8	Best practices when conducting and reporting a meta-analysis. , 2022, , 85-101.		0
9	Diagnosis and prognosis of COVID-19 employing analysis of patients' plasma and serum via LC-MS and machine learning. Computers in Biology and Medicine, 2022, 146, 105659.	3.9	12
10	Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses. International Journal of Antimicrobial Agents, 2022, 60, 106614.	1.1	2
11	Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis. World Journal of Urology, 2021, 39, 953-962.	1.2	19
12	Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19. American Journal of Infection Control, 2021, 49, 21-29.	1.1	354
13	Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharmacy Practice, 2021, 19, 2302.	0.8	17
14	Analysis of completeness for spontaneous reporting of disease-modifying therapies in multiple sclerosis. Expert Opinion on Drug Safety, 2021, 20, 1-6.	1.0	1
15	Implications of a defined daily dose fixed database for drug utilization research studies: The case of statins in Portugal. British Journal of Clinical Pharmacology, 2021, 87, 3542-3549.	1.1	3
16	Prognostic Factors, Survival Analyses and the Risk of Second Primary Cancer: A Population-Based Study on Burkitt Lymphoma/Leukemia. Diseases (Basel, Switzerland), 2021, 9, 43.	1.0	2
17	Publication speed in pharmacy practice journals: A comparative analysis. PLoS ONE, 2021, 16, e0253713.	1.1	11
18	Limitations and perceived delays for diagnosis and staging of lung cancer in Portugal: A nationwide survey analysis. PLoS ONE, 2021, 16, e0252529.	1.1	5

#	Article	IF	CITATIONS
19	Diagnosis and prediction of COVID-19 severity: can biochemical tests and machine learning be used as prognostic indicators?. Computers in Biology and Medicine, 2021, 134, 104531.	3.9	39
20	Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 514-525.	0.2	1
21	Lag times in the publication of network meta-analyses: a survey. BMJ Open, 2021, 11, e048581.	0.8	4
22	Prevalence of rheumatoid arthritis in South America: a systematic review and meta-analysis. Ciencia E Saude Coletiva, 2021, 26, 5371-5382.	0.1	4
23	Reports of substandard medicines: a lexicographic analysis of the Brazilian Health Surveillance Report System. Revista De Ciencias Farmaceuticas Basica E Aplicada, 2021, 42, e753.	0.2	0
24	Evaluation of the epidemiological aspects and the impact of COVID-19 on tuberculosis notifications in SÃ \pm o Paulo. Revista De Ciencias Farmaceuticas Basica E Aplicada, 2021, 42, .	0.2	0
25	Vitamins, antioxidants, and type 2 diabetes. , 2020, , 373-383.		1
26	Pharmacy practice research – A call to action. Research in Social and Administrative Pharmacy, 2020, 16, 1602-1608.	1.5	33
27	A multivariate analysis of risk factors associated with death by Covid-19 in the USA, Italy, Spain, and Germany. Zeitschrift Fur Gesundheitswissenschaften, 2020, , 1-7.	0.8	10
28	Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0238910.	1.1	61
29	Reducing oral corticosteroids in severe asthma (ROSA Project): a nationwide Portuguese consensus. Pulmonology, 2020, 27, 313-327.	1.0	7
30	Mapping the characteristics of meta-analyses of pharmacy services: a systematic review. International Journal of Clinical Pharmacy, 2020, 42, 1252-1260.	1.0	10
31	Five-year survival analysis and predictors of death in HIV-positive serology patients attending the Military Hospital of Nampula, Mozambique. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 1379-1387.	0.6	2
32	Safety and Efficacy of Oral Anticoagulants Therapies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-Analysis. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 399-408.	1.0	3
33	How many manuscripts should I peer review per year?. Pharmacy Practice, 2020, 18, 1804.	0.8	13
34	Impact of Pharmacistâ€led Discharge Counseling on Hospital Readmission and Emergency Department Visits: A Systematic Review and Metaâ€analysis. Journal of Hospital Medicine, 2020, 15, 52-59.	0.7	10
35	Risk factors associated with delay in diagnosis and mortality in patients with COVID-19 in the city of Rio de Janeiro, Brazil. Ciencia E Saude Coletiva, 2020, 25, 4131-4140.	0.1	33
36	Evaluation of the application of the Diabetes Quality of Life Questionnaire in patients with diabetes mellitus. Archives of Endocrinology and Metabolism, 2020, 64, 59-65.	0.3	11

#	Article	IF	CITATIONS
37	Information Sources for Pharmacy Practice Researchers. , 2020, , 219-235.		O
38	An innovative and comprehensive technique to evaluate different measures of medication adherence: The network meta-analysis. Research in Social and Administrative Pharmacy, 2019, 15, 358-365.	1.5	15
39	Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. Endocrine, 2019, 63, 18-26.	1.1	28
40	Systematic Review and Metaâ€Analysis of Medication Reviews Conducted by Pharmacists on Cardiovascular Diseases Risk Factors in Ambulatory Care. Journal of the American Heart Association, 2019, 8, e013627.	1.6	25
41	The Impact of Flt3 Gene Mutations in Acute Promyelocytic Leukemia: A Meta-Analysis. Cancers, 2019, 11, 1311.	1.7	33
42	Mapping pharmacy journals: A lexicographic analysis. Research in Social and Administrative Pharmacy, 2019, 15, 1464-1471.	1.5	28
43	Usability and sensitivity of the risk of bias assessment tool for randomized controlled trials of pharmacist interventions. International Journal of Clinical Pharmacy, 2019, 41, 785-792.	1.0	5
44	Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network metaâ€analysis. British Journal of Clinical Pharmacology, 2019, 85, 2280-2291.	1.1	23
45	Temporal effectiveness of interventions to improve medication adherence: A network meta-analysis. PLoS ONE, 2019, 14, e0213432.	1.1	41
46	Description of network meta-analysis geometry: A metrics design study. PLoS ONE, 2019, 14, e0212650.	1.1	30
47	Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder. International Clinical Psychopharmacology, 2019, 34, 57-64.	0.9	8
48	Methodological quality assessment of network meta-analysis of drug interventions: implications from a systematic review. International Journal of Epidemiology, 2019, 48, 620-632.	0.9	22
49	Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies. Diagnostic Microbiology and Infectious Disease, 2019, 94, 41-49.	0.8	55
50	Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses. Journal of Attention Disorders, 2019, 23, 111-120.	1.5	9
51	Using Cell Cultures for the Investigation of Treatments for Attention Deficit Hyperactivity Disorder: A Systematic Review. Current Neuropharmacology, 2019, 17, 916-925.	1.4	9
52	Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis. European Child and Adolescent Psychiatry, 2018, 27, 1335-1345.	2.8	40
53	DIRECT COSTS OF TYPE 2 DIABETES: A BRAZILIAN COST-OF-ILLNESS STUDY. International Journal of Technology Assessment in Health Care, 2018, 34, 180-188.	0.2	9
54	Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis. Value in Health, 2018, 21, 874-880.	0.1	12

#	Article	IF	CITATIONS
55	Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies. Clinical Drug Investigation, 2018, 38, 389-400.	1.1	17
56	Antioxidant effects of vitamins in type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetology and Metabolic Syndrome, 2018, 10, 18.	1.2	72
57	Treatment interruption of biological drugs and tofacitinib in rheumatoid arthritis: A systematic review of case reports. Brazilian Journal of Pharmaceutical Sciences, 2018, 54, .	1.2	2
58	Comparison of Interventions to Improve Long-Term Medication Adherence Across Different Clinical Conditions: A Systematic Review With Network Meta-Analysis. Frontiers in Pharmacology, 2018, 9, 1454.	1.6	27
59	Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis. European Journal of Cancer, 2018, 104, 9-20.	1.3	21
60	Antidiabetic potential of Musa spp. inflorescence: a systematic review. Journal of Pharmacy and Pharmacology, 2018, 70, 1583-1595.	1.2	7
61	Mapping the characteristics of network meta-analyses on drug therapy: A systematic review. PLoS ONE, 2018, 13, e0196644.	1.1	12
62	Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-Analysis. CNS Drugs, 2018, 32, 813-826.	2.7	50
63	Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2018, 74, 1513-1521.	0.8	3
64	Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS). BioDrugs, 2018, 32, 377-390.	2.2	10
65	Costâ€effectiveness of amphotericin B formulations in the treatment of systemic fungal infections. Mycoses, 2018, 61, 754-763.	1.8	28
66	Suporte Social e HIV: Relações Entre CaracterÃsticas ClÃnicas, Sociodemográficas e Adesão ao Tratamento. Psicologia: Teoria E Pesquisa, 2018, 34, .	0.1	2
67	Fluconazole Doses Used for Prophylaxis of Invasive Fungal Infection in Neonatal Intensive Care Units: A Network Meta-Analysis. Journal of Pediatrics, 2017, 185, 129-135.e6.	0.9	19
68	Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. Clinical Drug Investigation, 2017, 37, 635-646.	1.1	18
69	A network meta-analysis of primary prophylaxis for invasive fungal infection in haematological patients. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 530-538.	0.7	16
70	Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis. Journal of Pharmacy and Pharmacology, 2017, 69, 1672-1683.	1.2	43
71	Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 749-755.	1.4	13
72	Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24. European Journal of Clinical Pharmacology, 2017, 73, 1-14.	0.8	10

#	Article	IF	CITATIONS
73	Efficacy and safety of amphotericin B lipidâ€based formulations—A systematic review and metaâ€analysis. Mycoses, 2017, 60, 146-154.	1.8	50
74	New drugs for the treatment of agitation in schizophrenia: a systematic review and meta-analysis of inhaled loxapine and infused sodium nitroprusside. Acta Scientiarum - Health Sciences, 2017, 39, 81.	0.2	0
75	Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharmacy Practice, 2017, 15, 943-943.	0.8	243
76	Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study. Therapeutics and Clinical Risk Management, 2017, Volume 13 , 59 - 64 .	0.9	5
77	METFORMIN USAGE TO INDUCE OVULATION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: META-ANALYSIS. International Journal of Pharmacy and Pharmaceutical Sciences, 2016, 8, 86.	0.3	2
78	Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy. Core Evidence, 2016, Volume 11, 49-61.	4.7	18
79	Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 478-485.	0.7	20
80	Analysis of ten years of publishing in Pharmacy Practice. Pharmacy Practice, 2016, 14, 847.	0.8	4
81	Impact of Natural Juice Consumption on Plasma Antioxidant Status: A Systematic Review and Meta-Analysis. Molecules, 2015, 20, 22146-22156.	1.7	25
82	The nonsteroidal antiinflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model of Parkinson's disease. Neuroscience, 2015, 300, 246-253.	1.1	28
83	Adverse events and treatment failure leading to discontinuation of recently approved antipsychotic drugs in schizophrenia: A network meta-analysis. Schizophrenia Research, 2015, 169, 483-485.	1.1	4
84	PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 53, 35-44.	2.5	86
85	Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. Behavioural Brain Research, 2014, 274, 390-399.	1.2	75
86	Allergic Contact Dermatitis after the Use of Cosmetics Containing Parabens: Systematic Review and Meta-analysis. Brazilian Archives of Biology and Technology, 0, 65, .	0.5	1